Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M38.4Revenue (TTM) $M0.1Net Margin (%)-39,128.0Altman Z-Score-34.8
Enterprise Value $M28.2EPS (TTM) $-0.8Operating Margin %-39,128.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-39,128.0Higher ROA y-yN
Price/Book4.610-y EBITDA Growth Rate %-16.3Quick Ratio4.6Cash flow > EarningsY
Price/Sales7595-y EBITDA Growth Rate %14.1Current Ratio4.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-111.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-129.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M25.4ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RPRXCharles Brandes 2016-09-30 Buy $1.64 - $2.28
($1.98)
$ 1.51-24%New holding18,000
RPRXJohn Paulson 2014-12-31 Sold Out -0.04%$6.02 - $10.69
($8.49)
$ 1.51-82%Sold Out0
RPRXJohn Paulson 2014-09-30 Buy 0.04%$8.77 - $22.16
($14.84)
$ 1.51-90%New holding1,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RPRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PODOLSKI JOSEPHPresident and CEO 2016-12-09Buy20,000$1.6-5.63view
Masterson Nola EDirector 2016-11-21Sell3,305$1.95-22.56view
PODOLSKI JOSEPHPresident and CEO 2016-02-18Buy10,000$0.9362.37view
PODOLSKI JOSEPHPresident and CEO 2016-01-07Buy11,677$1.1827.97view
Anderson KatherineCFO 2014-11-12Buy3,500$9.41-83.95view
PODOLSKI JOSEPHPresident and CEO 2014-11-12Buy4,700$9.42-83.97view
Masterson Nola EDirector 2014-09-15Buy200$14.34-89.47view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-89.14view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-89.1view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-89.91view

Quarterly/Annual Reports about RPRX:

News about RPRX:

Articles On GuruFocus.com
Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 
Repros Therapeutics Inc. (RPRX) CEO Joseph Podolski buys 4,000 Shares Mar 05 2009 
Weekly CEO Buys Highlight: Medtox Scientific Inc., Provident Bankshares Corp., Escalade Inc., Repros Apr 25 2008 

More From Other Websites
7 Companies That Destroyed Shareholders Last Week Dec 10 2016
Repros Therapeutics Drops on FDA Vote Dec 07 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Dec 07 2016
FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism Dec 06 2016
10 Major Pharma and FDA Catalysts Coming in December Dec 05 2016
REPROS THERAPEUTICS INC. Financials Nov 17 2016
Repros Therapeutics upgraded by Ladenburg Thalmann Nov 16 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Nov 15 2016
Repros (RPRX) Reports Positive Top-Line Data on Proellex Nov 15 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Nov 14 2016
Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex® Delivered... Nov 14 2016
Repros (RPRX) Loss Narrower Y/Y in Q3, Pipeline in Focus Nov 09 2016
REPROS THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report Nov 09 2016
Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results Nov 08 2016
Repros Therapeutics reports 3Q loss Nov 08 2016
Repros Therapeutics reports 3Q loss Nov 08 2016
Repros Therapeutics reports 3Q loss Nov 08 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition Nov 08 2016
Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results Nov 08 2016
What to Expect from Repros (RPRX) This Earnings Season Nov 03 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)